BioSpace News Archive

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Orphan Drug Designation (ODD) for SLS-005 in mucopolysaccharidosis type III (MPS III), Sanfilippo syndrome, from the European Medicines Agency (EMA).

Summer is Lyme disease season; and while no age group is immune from potential infection, the disproportionate incidents in children is a stark reality that needs addressing.

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the successful completion of a proof-of-concept (POC) clinical study using a wearable myopia control device based on Kubota Glasses technology.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enrolled the first two patients for its first-in-human CoreoGraft study.

Recordati Rare Diseases Inc., today announced the U.S. Food and Drug Administration (FDA) has approved CYSTADROPS® (cysteamine ophthalmic solution) 0.37%. CYSTADROPS is a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and B. Braun Medical Inc., a global market leader1 in regional anesthesia and pain management, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Onvision®, a breakthrough ultrasound guidance solution for real-time needle tip tracking.

New Foundation grant to fund innovative projects, national convenings and education programs that will enhance the skills of all health care providers and improve the experience of patients

A recent study has concluded that WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous cells in the esophagus, is a cost-effective adjunct to forceps biopsies when screening for Barrett’s esophagus (BE).

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), today announced that it has engaged with certain shareholders to enter into voluntary lock-up agreements (the “Lock-up Agreements”) applying resale restrictions on up to 52,908,420 common shares (the “Restricted Shares”) extending the period of time before the shares become free trading.